Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2024-07-03 00:00:00 ET · period of report 2024-07-01 · accession 0000950170-24-081258 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-07-03 | 2024-07-01 | NTLA | Dube Michael P | VP, PAO, Interim PFO | A - Grant | $0.00 | +17.8K | 49.0K | +57% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-01 | A | A | 17,801 | $0.00 | 49,024 | D | — | — | (F1) Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |